KRAS, the oncogene, has the highest mutation rate among all cancers. Related to the high mutation rate, KRAS is linked to many fatal cancers, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Advancements in KRAS as a drug target show potential for treating many life-threatening tumors (Huang et al, 2021).
KRAS was once deemed "undruggable" due to its intrinsic protein factors. A recent discovery of a new allosteric binding site on KRAS mutation KRAS (G12C) reignited interest in KRAS and KRAS inhibitors for therapeutic cancer treatments. The drug AMG510 (Sotorasib), which specifically targets this mutation, was the first KRAS drug approved for clinical use (Huang et al, 2021).
The Transcreener GDP KRAS Assay is an excellent tool for researchers examining KRAS for therapeutic treatments.